Fully agree the AVATAR outcome is transformational, as it marks the last data set for RETT adult as our first pathway to an NDA...and I'm talking a few months not a year.
#2 would be PDD OLE data. I still hold out hope that their strategy may involve filing for approval with in-hand Phase 2b/3 data and could gain a (conditional) US approval. I fully expect they file with the TGA with what they have for both PDD and Rett. Let's not under-estimate the rest-of-world market and that some ROW approvals may (likely) come ahead of the FDA.
Market Data 
Markets 
AI
